TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prioritising and Optimising Multiple Medications in Elderly Multimorbid Patients in General Practice. - A Pragmatic Cluster-randomised Controlled Trial.
Brief Summary: Objective: To investigate whether the complex intervention will improve the appropriateness of prescriptions in elderly multi-morbid patients with multi-medication in general practices.

Study hypothesis: The primary objective of the study is to determine whether the complex intervention will improve the appropriateness of prescriptions compared to usual care. The primary efficacy endpoint is the change in the Medication Appropriateness Index (MAI) score from baseline (T0) to 6 months after baseline (T1), i.e. the difference MAI T1-T0.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention arm; Type: EXPERIMENTAL; Interventions: Other: Optimization strategy (complex intervention) | Intervention Type: OTHER; Name: Optimization strategy (complex intervention); Assigned to Arm(s): Intervention arm
B: Arm Label: Pharmacist Intervention; Type: EXPERIMENTAL; Interventions: Procedure: Pharmacist Intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Pharmacist Intervention; Assigned to Arm(s): Pharmacist Intervention
C: Arm Label: Optimization of drug prescribing; Type: EXPERIMENTAL; Interventions: Other: Optimization of drug prescribing | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Optimization of drug prescribing; Assigned to Arm(s): Optimization of drug prescribing
D: Arm Label: Intervention; Type: OTHER; Interventions: Other: E-learning | Arm Label: Control; Type: OTHER; Interventions: Other: E-learning | Intervention Type: OTHER; Name: E-learning; Assigned to Arm(s): Control, Intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation and Monitoring of Perioperative Management of Patients With Coronary Stents Undergoing Noncardiac Surgery
Brief Summary: The purpose of this study is to evaluate and monitor perioperative management of patients with coronary stents undergoing noncardiac surgery.

Objectives:

* To describe the incidence and severity of adverse cardiovascular events in patients with coronary stents undergoing noncardiac surgery with admission.
* To assess the following-up of the guidelines about the perioperative management of antiplatelet therapy in these patients.
* To assess the relationship between the incidence of cardiac or neurovascular events, as well as bleeding complications with the perioperative management of antiplatelet therapy.
* Number of Participants with Adverse Events as a Measure of Safety


Options:
A: Intervention Type: PROCEDURE; Name: Acute abdominal surgery; Assigned to Arm(s): N/A
B: N/A
C: N/A
D: Arm Label: Coronary Stent; Type: N/A; Interventions: N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Intermittent Hepatic Inflow Occlusion During Donor Hepatectomy In Adult Living Donor Liver Transplantation Using Right Hemiliver Grafts
Brief Summary: Intermittent hepatic inflow occlusion (IHIO), also called Pringle maneuver, is a safe and effective procedure for major hepatectomy in patients with liver disease. In addition, ischemic preconditioning with IHIO has been reported to have protective effects in patients undergoing liver resection. The role of IHIO, however, has not been fully elucidated in donors and recipients during living donor liver transplantation.


Options:
A: Arm Label: Standard fluid management; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard fluid management | Arm Label: Goal directed fluid therapy; Type: ACTIVE_COMPARATOR; Interventions: Device: Goal directed fluid therapy with the Edwards EV1000 system | Intervention Type: PROCEDURE; Name: Standard fluid management; Assigned to Arm(s): Standard fluid management | Intervention Type: DEVICE; Name: Goal directed fluid therapy with the Edwards EV1000 system; Assigned to Arm(s): Goal directed fluid therapy
B: Arm Label: Clamp-Crushing technique; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Clamp-Crushing technique | Arm Label: BiClamp forceps hepatectomy; Type: EXPERIMENTAL; Interventions: Device: BiClamp forceps | Intervention Type: PROCEDURE; Name: Clamp-Crushing technique; Assigned to Arm(s): Clamp-Crushing technique | Intervention Type: DEVICE; Name: BiClamp forceps; Assigned to Arm(s): BiClamp forceps hepatectomy
C: N/A
D: Arm Label: IHIO; Type: EXPERIMENTAL; Interventions: Procedure: Intermittent hepatic inflow occlusion (IHIO) | Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Procedure: Intermittent hepatic inflow occlusion (IHIO) | Intervention Type: PROCEDURE; Name: Intermittent hepatic inflow occlusion (IHIO); Assigned to Arm(s): Control, IHIO

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy, Immunogenicity and Safety of Two Doses of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Liquid Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants
Brief Summary: The purpose of this study is to assess the efficacy, immunogenicity and safety of GSK Biologicals' liquid human rotavirus vaccine in healthy Chinese infants 6 to 16 weeks of age.


Options:
A: Arm Label: Rotavirus vaccine (BRV-PV); Type: EXPERIMENTAL; Interventions: Biological: Rotavirus vaccine (BRV-PV) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Rotavirus vaccine (BRV-PV); Assigned to Arm(s): Rotavirus vaccine (BRV-PV) | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: BIOLOGICAL; Name: 2-dose oral live attenuated G1P[8] human rotavirus vaccine; Assigned to Arm(s): N/A
C: Arm Label: Rotarix Group; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals' liquid human rotavirus vaccine 444563, Biological: Infanrix™, Biological: Institute of Medical Biology Chinese Academy of Medical Sciences' Oral poliovirus vaccine (OPV) | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Biological: Infanrix™, Biological: Institute of Medical Biology Chinese Academy of Medical Sciences' Oral poliovirus vaccine (OPV) | Intervention Type: BIOLOGICAL; Name: GSK Biologicals' liquid human rotavirus vaccine 444563; Assigned to Arm(s): Rotarix Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group | Intervention Type: BIOLOGICAL; Name: Infanrix™; Assigned to Arm(s): Placebo Group, Rotarix Group | Intervention Type: BIOLOGICAL; Name: Institute of Medical Biology Chinese Academy of Medical Sciences' Oral poliovirus vaccine (OPV); Assigned to Arm(s): Placebo Group, Rotarix Group
D: Arm Label: 1; Type: OTHER; Interventions: Biological: Rotateq vaccine | Intervention Type: BIOLOGICAL; Name: Rotateq vaccine; Assigned to Arm(s): 1

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy, Immunogenicity and Safety of Two Doses of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Liquid Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants
Brief Summary: The purpose of this study is to assess the efficacy, immunogenicity and safety of GSK Biologicals' liquid human rotavirus vaccine in healthy Chinese infants 6 to 16 weeks of age.


Options:
A: Intervention Type: BIOLOGICAL; Name: 2-dose oral live attenuated G1P[8] human rotavirus vaccine; Assigned to Arm(s): N/A
B: Arm Label: Rotavin2H; Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Arm Label: Rotavin2L; Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Arm Label: Rotavin3H; Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Arm Label: Rotavin3L; Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Intervention Type: BIOLOGICAL; Name: Rotarix; Assigned to Arm(s): Rotavin2H, Rotavin2L, Rotavin3H, Rotavin3L
C: Arm Label: Rotarix Group; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals' liquid human rotavirus vaccine 444563, Biological: Infanrix™, Biological: Institute of Medical Biology Chinese Academy of Medical Sciences' Oral poliovirus vaccine (OPV) | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Biological: Infanrix™, Biological: Institute of Medical Biology Chinese Academy of Medical Sciences' Oral poliovirus vaccine (OPV) | Intervention Type: BIOLOGICAL; Name: GSK Biologicals' liquid human rotavirus vaccine 444563; Assigned to Arm(s): Rotarix Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group | Intervention Type: BIOLOGICAL; Name: Infanrix™; Assigned to Arm(s): Placebo Group, Rotarix Group | Intervention Type: BIOLOGICAL; Name: Institute of Medical Biology Chinese Academy of Medical Sciences' Oral poliovirus vaccine (OPV); Assigned to Arm(s): Placebo Group, Rotarix Group
D: Intervention Type: BIOLOGICAL; Name: Human rotavirus liquid vaccine; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase I Escalating Dose Ranging Study to Evaluate the Safety and Immunogenicity of the VAX128 A, B, and C Novel H1N1 Influenza Vaccine Constructs in Healthy Adults 18-49 Years of Age and in Community Living Adults ≥65 Years of Age
Brief Summary: This is a multicenter, escalating dose-ranging study to assess the safety, reactogenicity and immunogenicity of 3 different novel H1N1 influenza vaccine constructs delivered i.m. as a single dose vaccination on day 0.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Biological: VAX125 | Intervention Type: BIOLOGICAL; Name: VAX125; Assigned to Arm(s): A
B: Arm Label: Quadrivalent influenza vaccine GSK 2115160A Group 1; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals' quadrivalent influenza vaccine | Arm Label: Quadrivalent influenza vaccine GSK 2115160A Group 2; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals' quadrivalent influenza vaccine | Arm Label: Trivalent influenza vaccine GSK 2115160A Group 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: GSK Biologicals' trivalent influenza vaccine | Arm Label: Trivalent influenza vaccine GSK 2115160A Group 2; Type: ACTIVE_COMPARATOR; Interventions: Biological: GSK Biologicals' trivalent influenza vaccine | Intervention Type: BIOLOGICAL; Name: GSK Biologicals' quadrivalent influenza vaccine; Assigned to Arm(s): Quadrivalent influenza vaccine GSK 2115160A Group 1, Quadrivalent influenza vaccine GSK 2115160A Group 2 | Intervention Type: BIOLOGICAL; Name: GSK Biologicals' trivalent influenza vaccine; Assigned to Arm(s): Trivalent influenza vaccine GSK 2115160A Group 1, Trivalent influenza vaccine GSK 2115160A Group 2
C: Arm Label: A/H1N1 Vaccine Group 1; Type: EXPERIMENTAL; Interventions: Biological: Monovalent Subvirion A/H1N1 Influenza vaccine (7.5 µg of HA) | Arm Label: A/H1N1 Vaccine Group 2; Type: EXPERIMENTAL; Interventions: Biological: Monovalent Subvirion A/H1N1 Influenza vaccine (15 µg of HA) | Arm Label: A/H1N1 Vaccine Group 3; Type: EXPERIMENTAL; Interventions: Biological: Monovalent Subvirion A/H1N1 Influenza vaccine (30 µg of HA) | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Normal saline solution (placebo) | Intervention Type: BIOLOGICAL; Name: Monovalent Subvirion A/H1N1 Influenza vaccine (7.5 µg of HA); Assigned to Arm(s): A/H1N1 Vaccine Group 1 | Intervention Type: BIOLOGICAL; Name: Monovalent Subvirion A/H1N1 Influenza vaccine (15 µg of HA); Assigned to Arm(s): A/H1N1 Vaccine Group 2 | Intervention Type: BIOLOGICAL; Name: Monovalent Subvirion A/H1N1 Influenza vaccine (30 µg of HA); Assigned to Arm(s): A/H1N1 Vaccine Group 3 | Intervention Type: BIOLOGICAL; Name: Normal saline solution (placebo); Assigned to Arm(s): Placebo Group
D: Arm Label: VAX128; Type: EXPERIMENTAL; Interventions: Biological: VAX128 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: VAX128; Assigned to Arm(s): VAX128 | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Apathy in Alzheimer's Disease With Modafinil
Brief Summary: This study examined the effects of modafinil on apathetic symptomatology, performance of activities of daily living (ADLs) and caregiver burden in individuals with Alzheimer's disease (AD).


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Valproate | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Valproate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 100 mg LY450139; Type: EXPERIMENTAL; Interventions: Drug: LY450139 | Arm Label: 140 mg LY450139; Type: EXPERIMENTAL; Interventions: Drug: LY450139 | Intervention Type: DRUG; Name: LY450139; Assigned to Arm(s): 100 mg LY450139, 140 mg LY450139 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Cholinesterase inhibitor only; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cholinesterase Plus Modafinil; Type: EXPERIMENTAL; Interventions: Drug: Modafinil | Intervention Type: DRUG; Name: Modafinil; Assigned to Arm(s): Cholinesterase Plus Modafinil | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cholinesterase inhibitor only
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Methylphenidate | Arm Label: Arm 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): Arm 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Arm 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Reducing Cervical Cancer in Appalachia
Brief Summary: To increase early detection of cervical cancer by increasing the proportion of Appalachian women, age 18 and older, who receive Pap smears at appropriate intervals and return for follow-up care when necessary.


Options:
A: Arm Label: Intervention and control; Type: ACTIVE_COMPARATOR; Interventions: Other: Screening without fee | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Screening without fee; Assigned to Arm(s): Intervention and control
B: Intervention Type: DEVICE; Name: online health information journal; Assigned to Arm(s): N/A
C: Arm Label: Early Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lay health advisor visits and newsletter | Arm Label: Delayed Intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Lay health advisor visits and newsletter; Assigned to Arm(s): Early Intervention
D: Arm Label: Usual Care Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care Group | Arm Label: Lay Health Advisor Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lay Health Advisor Education Intervention | Intervention Type: BEHAVIORAL; Name: Lay Health Advisor Education Intervention; Assigned to Arm(s): Lay Health Advisor Intervention | Intervention Type: BEHAVIORAL; Name: Usual Care Group; Assigned to Arm(s): Usual Care Group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Acute Hemodynamic Effects of Riociguat (BAY63-2521) in Patients With Pulmonary Hypertension Associated With Diastolic Heart Failure: A Randomized, Double-blind, Placebo-controlled, Single-dose Study in Three Ascending Dose Cohorts
Brief Summary: The aim of this study is to assess whether single oral doses of Riociguat safely improve the cardiovascular function in patients with pulmonary hypertension associated with left ventricular diastolic dysfunction


Options:
A: Arm Label: Riociguat (Adempas, BAY63-2521) up to 2.5 mg_IDT; Type: EXPERIMENTAL; Interventions: Drug: Riociguat (Adempas, BAY63-2521) | Arm Label: Riociguat (Adempas, BAY63-2521) up to 1.5 mg_IDT; Type: EXPERIMENTAL; Interventions: Drug: Riociguat (Adempas, BAY63-2521) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Riociguat (Adempas, BAY63-2521); Assigned to Arm(s): Riociguat (Adempas, BAY63-2521) up to 2.5 mg_IDT | Intervention Type: DRUG; Name: Riociguat (Adempas, BAY63-2521); Assigned to Arm(s): Riociguat (Adempas, BAY63-2521) up to 1.5 mg_IDT | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Riociguat (Adempas, BAY63-2521) | Intervention Type: DRUG; Name: Riociguat (Adempas, BAY63-2521); Assigned to Arm(s): Arm 1
C: Arm Label: Riociguat (Adempas, BAY63-2521) up to 2.5 mg_IDT; Type: EXPERIMENTAL; Interventions: Drug: Riociguat (Adempas, BAY63-2521), Drug: Sildenafil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Sildenafil | Intervention Type: DRUG; Name: Riociguat (Adempas, BAY63-2521); Assigned to Arm(s): Riociguat (Adempas, BAY63-2521) up to 2.5 mg_IDT | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Sildenafil; Assigned to Arm(s): Placebo, Riociguat (Adempas, BAY63-2521) up to 2.5 mg_IDT
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Riociguat (BAY63-2521) | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Riociguat (BAY63-2521) | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: Riociguat (BAY63-2521) | Arm Label: Arm 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Riociguat (BAY63-2521); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Riociguat (BAY63-2521); Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: Riociguat (BAY63-2521); Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 4

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Efficacy of a Brief Motivational Enhancement Education Programme on Continuous Positive Airway Pressure Adherence in Obstructive Sleep Apnea: A Randomised Controlled Trial
Brief Summary: The purpose of this study is to examine whether an education programme would enhance continuous positive airway pressure (CPAP) adherence.


Options:
A: Arm Label: Telemedecine; Type: EXPERIMENTAL; Interventions: Device: Telemedicine | Arm Label: Standard Care; Type: ACTIVE_COMPARATOR; Interventions: Device: Standard care | Intervention Type: DEVICE; Name: Telemedicine; Assigned to Arm(s): Telemedecine | Intervention Type: DEVICE; Name: Standard care; Assigned to Arm(s): Standard Care
B: Arm Label: Standard care (SC); Type: SHAM_COMPARATOR; Interventions: Behavioral: CPAP education | Arm Label: Extended education (ME+SC); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CPAP education | Intervention Type: BEHAVIORAL; Name: CPAP education; Assigned to Arm(s): Extended education (ME+SC), Standard care (SC)
C: Arm Label: Standard Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard care | Arm Label: Intensive care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Intensive care | Intervention Type: BEHAVIORAL; Name: Standard care; Assigned to Arm(s): Standard Care | Intervention Type: BEHAVIORAL; Name: Intensive care; Assigned to Arm(s): Intensive care
D: Arm Label: placebo exercices; Type: PLACEBO_COMPARATOR; Interventions: Device: Continuous Positive Airway Pressure (CPAP) | Arm Label: phonoaudiologic therapy; Type: ACTIVE_COMPARATOR; Interventions: Device: Continuous Positive Airway Pressure (CPAP) | Intervention Type: DEVICE; Name: Continuous Positive Airway Pressure (CPAP); Assigned to Arm(s): phonoaudiologic therapy, placebo exercices

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Renal Artery Stenosis in Coronary Artery Disease: Medical Therapy Versus Medical Therapy Plus Renal Artery Stenting in Preventing Cardiac and Renal Outcomes. The Rationale and Study Design of a Prospective,Randomized Trial: the RASCAD Study
Brief Summary: The Stenting of Renal Artery Stenosis in Coronary Artery Disease (RASCAD) study is a randomized controlled trial designed to evaluate the effect of renal artery stenting+medical therapy versus medical therapy alone on left ventricular mass progression and cardiovascular morbidity and mortality in patients affected by coronary artery disease and renal artery stenosis.


Options:
A: Arm Label: Drug therapy; Type: PLACEBO_COMPARATOR; Interventions: Drug: Medical therapy | Arm Label: Drug therapy + stenting angioplasty; Type: EXPERIMENTAL; Interventions: Procedure: stenting angioplasty plus medical therapy | Intervention Type: PROCEDURE; Name: stenting angioplasty plus medical therapy; Assigned to Arm(s): Drug therapy + stenting angioplasty | Intervention Type: DRUG; Name: Medical therapy; Assigned to Arm(s): Drug therapy
B: Arm Label: aspirin, clopidogrel & sarpogrelate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sarpogrelate, Drug: Aspirin, Drug: Clopidogrel | Arm Label: aspirin, clopidogrel & placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Aspirin, Drug: Clopidogrel, Drug: Placebo (for Sarpogrelate) | Intervention Type: DRUG; Name: Sarpogrelate; Assigned to Arm(s): aspirin, clopidogrel & sarpogrelate | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): aspirin, clopidogrel & placebo, aspirin, clopidogrel & sarpogrelate | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): aspirin, clopidogrel & placebo, aspirin, clopidogrel & sarpogrelate | Intervention Type: DRUG; Name: Placebo (for Sarpogrelate); Assigned to Arm(s): aspirin, clopidogrel & placebo
C: Arm Label: sarpogrelate 300 mg per day; Type: EXPERIMENTAL; Interventions: Drug: sarpogrelate | Arm Label: No sarpogrelate medication; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: sarpogrelate; Assigned to Arm(s): sarpogrelate 300 mg per day
D: Arm Label: TRK-100STP; Type: EXPERIMENTAL; Interventions: Drug: TRK-100STP high dose, Drug: TRK-100STP low dose | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: TRK-100STP high dose; Assigned to Arm(s): TRK-100STP | Intervention Type: DRUG; Name: TRK-100STP low dose; Assigned to Arm(s): TRK-100STP | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A